Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety
作者:Mengwei Zhu、Tiantian Fu、Mengyuan You、Junyuan Cao、Hanxi Yang、Xinyao Chen、Qiumeng Zhang、Yechun Xu、Xiangrui Jiang、Leike Zhang、Haixia Su、Yan Zhang、Jingshan Shen
DOI:10.1016/j.bmc.2023.117316
日期:2023.5
In this paper, a series of peptidomimetic SARS-CoV-2 3CL protease inhibitors with new P2 and P4 positions were synthesized and evaluated. Among these compounds, 1a and 2b exhibited obvious 3CLpro inhibitory activities with IC50 of 18.06 nM and 22.42 nM, respectively. 1a and 2b also showed excellent antiviral activities against SARS-CoV-2 in vitro with EC50 of 313.0 nM and 170.2 nM, respectively, the
本文合成并评估了一系列具有新P 2 和P 4 位点的拟肽 SARS-CoV-2 3CL 蛋白酶抑制剂。其中, 1a和2b表现出明显的3CL前体抑制活性,IC 50分别为18.06 nM和22.42 nM。 1a和2b在体外也表现出优异的针对SARS-CoV-2的抗病毒活性,EC 50分别为313.0 nM和170.2 nM, 1a和2b的抗病毒活性分别比nirmatrelvir好2倍和4倍。体外研究表明这两种化合物没有明显的细胞毒性。进一步的代谢稳定性测试和药代动力学研究表明, 1a和2b在肝微粒体中的代谢稳定性显着提高, 2b在小鼠体内的药代动力学参数与尼马瑞韦相似。